Breakthrough is committed to funding research to improve cancer care and outcomes and to ensure patient benefit is at the core of our efforts. Breakthrough will achieve its strategic objectives through increased investment and focus on these research priorities over the next several years.
Specifically, we will:
Increase our research investment into poor prognosis cancers and currently incurable cancers prioritising lung, oesophageal, ovarian and pancreatic cancers.
Continue to significantly invest in research on the role of the immune system in cancer development and identify opportunities to harness the immune system to control and eradicate metastatic cancers.
Improve integration of cancer research into cancer care in Ireland by prioritising funding for projects and infrastructure with significant clinical engagement / input.
Continue to discover and develop new therapeutics and surgical approaches / technologies, including increased investment in biological and immunotherapies.
Continue to fund research, which aims to improve the effectiveness or specificity of current cancer therapies including investing in biomarkers discovery, nutrition and therapeutic delivery.
Invest in research-led innovation at every stage of the cancer patient journey from first diagnosis through to treatment, clinical trials and palliative care to improve survival and quality of life.
Our research encompasses a number of themes in the field of cancer prevention, diagnosis and treatment.